

June 2022

# medical benefit specialty drug update **bulletin**

Specialty Drug Program Updates for UnitedHealthcare Commercial, Community Plan, Medicare Advantage, and Individual & Family Plans

Review the following table to determine changes to our specialty medical injectable drug programs.

## SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

Drug Name	UnitedHealthcare Commercial	UnitedHealthcare Community Plan	UnitedHealthcare Medicare Advantage	UnitedHealthcare Individual & Family	Treatment Uses
<b>Byooviz™ (ranibizumab-nuna)</b>	X	X		X	Indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization.



To view the **UnitedHealthcare Commercial Plan** Review at Launch Medication List, go to [UHCprovider.com](https://UHCprovider.com) > Policies and Protocols > Commercial Policies > Medical & Drug Policies and Coverage Determination Guidelines for UnitedHealthcare Commercial Plans > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#).

To view the **UnitedHealthcare Community Plan** Review at Launch Drug List Plan, go to [UHCprovider.com](https://UHCprovider.com) > Policies and Protocols > Community Plan Policies > Medical & Drug Policies and Coverage Determination Guidelines for Community Plan > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#).

For **UnitedHealthcare Medicare Advantage**, Review at Launch drugs are added as Review at Launch Part B Medications in the *Medications/Drugs (Outpatient/Part B) Coverage Summary*. To view the summary, go to [UHCprovider.com](https://UHCprovider.com) > Policies and Protocols > Medicare Advantage Policies > Coverage Summaries for Medicare Advantage Plans > [Medications/Drugs \(Outpatient/Part B\) – Medicare Advantage Coverage Summary](#) > *Attachment A: Guideline 5 – Other Examples of Specific Drugs/Medications*.

To view the **UnitedHealthcare Individual & Family Plan** Review at Launch Medication List, go to [UHCprovider.com](https://UHCprovider.com) > Policies and Protocols > For Exchange Plans > Medical & Drug Policies and Coverage Determination Guidelines for UnitedHealthcare Individual Exchange Plans > *Review at Launch for New to Market Medications* > [Review at Launch Medication List](#)



## **New and Updated Procedure Codes for Injectable Medications – Effective July 1<sup>st</sup>, 2022**

Effective July 1, 2022, new procedure codes were created for certain drugs due to updates from the Centers for Medicare & Medicaid Services (CMS). Correct coding rules dictate that assigned and permanent codes should be used when available. The following injectable medications will have new codes:

- **Apretude**<sup>™</sup> (cabotegravir) – J0739
- **Carvykti**<sup>™</sup> (ciltacabtagene autoleucel) – C9098
- **Cutaquig**<sup>®</sup> (immune globulin) – J1551
- **Enjaymo**<sup>™</sup> (sutimlimab-jome) – C9094
- **Leqvio**<sup>®</sup> (inclisiran) – J1306
- **Releuko**<sup>®</sup> (filgrastim-ayow) – C9096
- **Ryplazim**<sup>®</sup> (plasminogen, human-tvmh) – J2998
- **Susvimo**<sup>™</sup> (ranibizumab) – J2779
- **Tezspire**<sup>™</sup> (tezepelumab-ekko) – J2356
- **Vabysmo**<sup>™</sup> (faricimab-svoa) – C9097
- **Vyvgart**<sup>®</sup> (efgartigimod alfa-fcab) – J9332